219 related articles for article (PubMed ID: 23614566)
1. Potential role of CYP2D6 in the central nervous system.
Cheng J; Zhen Y; Miksys S; Beyoğlu D; Krausz KW; Tyndale RF; Yu A; Idle JR; Gonzalez FJ
Xenobiotica; 2013 Nov; 43(11):973-84. PubMed ID: 23614566
[TBL] [Abstract][Full Text] [Related]
2. Human CYP2D6 Is Functional in Brain In Vivo: Evidence from Humanized CYP2D6 Transgenic Mice.
Tolledo C; Stocco MR; Miksys S; Gonzalez FJ; Tyndale RF
Mol Neurobiol; 2020 Jun; 57(6):2509-2520. PubMed ID: 32189192
[TBL] [Abstract][Full Text] [Related]
3. Effects of monoamine oxidase inhibitor and cytochrome P450 2D6 status on 5-methoxy-N,N-dimethyltryptamine metabolism and pharmacokinetics.
Shen HW; Wu C; Jiang XL; Yu AM
Biochem Pharmacol; 2010 Jul; 80(1):122-8. PubMed ID: 20206139
[TBL] [Abstract][Full Text] [Related]
4. Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates.
Yu AM; Idle JR; Gonzalez FJ
Drug Metab Rev; 2004 May; 36(2):243-77. PubMed ID: 15237854
[TBL] [Abstract][Full Text] [Related]
5. Human CYP2D6 and mouse CYP2Ds: organ distribution in a humanized mouse model.
Miksys SL; Cheung C; Gonzalez FJ; Tyndale RF
Drug Metab Dispos; 2005 Oct; 33(10):1495-502. PubMed ID: 16033950
[TBL] [Abstract][Full Text] [Related]
6. Modeling human cytochrome P450 2D6 metabolism and drug-drug interaction by a novel panel of knockout and humanized mouse lines.
Scheer N; Kapelyukh Y; McEwan J; Beuger V; Stanley LA; Rode A; Wolf CR
Mol Pharmacol; 2012 Jan; 81(1):63-72. PubMed ID: 21989258
[TBL] [Abstract][Full Text] [Related]
7. Effects of CYP2D6 status on harmaline metabolism, pharmacokinetics and pharmacodynamics, and a pharmacogenetics-based pharmacokinetic model.
Wu C; Jiang XL; Shen HW; Yu AM
Biochem Pharmacol; 2009 Sep; 78(6):617-24. PubMed ID: 19445902
[TBL] [Abstract][Full Text] [Related]
8. Human CYP2D6 in the Brain Is Protective Against Harmine-Induced Neurotoxicity: Evidence from Humanized CYP2D6 Transgenic Mice.
Stocco MR; Tolledo C; Wadji FB; Gonzalez FJ; Miksys S; Tyndale RF
Mol Neurobiol; 2020 Nov; 57(11):4608-4621. PubMed ID: 32761352
[TBL] [Abstract][Full Text] [Related]
9. Propranolol is a mechanism-based inhibitor of CYP2D and CYP2D6 in humanized CYP2D6-transgenic mice: Effects on activity and drug responses.
Tolledo EC; Miksys S; Gonzalez FJ; Tyndale RF
Br J Pharmacol; 2020 Feb; 177(3):701-712. PubMed ID: 31648367
[TBL] [Abstract][Full Text] [Related]
10. Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6.
Yu AM; Idle JR; Byrd LG; Krausz KW; Küpfer A; Gonzalez FJ
Pharmacogenetics; 2003 Mar; 13(3):173-81. PubMed ID: 12618595
[TBL] [Abstract][Full Text] [Related]
11. Cytochrome P450 2D6 as a model antigen.
Christen U; Holdener M; Hintermann E
Dig Dis; 2010; 28(1):80-5. PubMed ID: 20460894
[TBL] [Abstract][Full Text] [Related]
12. Altered expression of small heterodimer partner governs cytochrome P450 (CYP) 2D6 induction during pregnancy in CYP2D6-humanized mice.
Koh KH; Pan X; Shen HW; Arnold SL; Yu AM; Gonzalez FJ; Isoherranen N; Jeong H
J Biol Chem; 2014 Feb; 289(6):3105-13. PubMed ID: 24318876
[TBL] [Abstract][Full Text] [Related]
13. Determinants of Cytochrome P450 2D6 mRNA Levels in Healthy Human Liver Tissue.
Ning M; Duarte JD; Stevison F; Isoherranen N; Rubin LH; Jeong H
Clin Transl Sci; 2019 Jul; 12(4):416-423. PubMed ID: 30821899
[TBL] [Abstract][Full Text] [Related]
14. Mitochondrially targeted cytochrome P450 2D6 is involved in monomethylamine-induced neuronal damage in mouse models.
Chattopadhyay M; Chowdhury AR; Feng T; Assenmacher CA; Radaelli E; Guengerich FP; Avadhani NG
J Biol Chem; 2019 Jun; 294(26):10336-10348. PubMed ID: 31113867
[TBL] [Abstract][Full Text] [Related]
15. Anandamide oxidation by wild-type and polymorphically expressed CYP2B6 and CYP2D6.
Sridar C; Snider NT; Hollenberg PF
Drug Metab Dispos; 2011 May; 39(5):782-8. PubMed ID: 21289075
[TBL] [Abstract][Full Text] [Related]
16. Human NADPH-P450 oxidoreductase modulates the level of cytochrome P450 CYP2D6 holoprotein via haem oxygenase-dependent and -independent pathways.
Ding S; Yao D; Deeni YY; Burchell B; Wolf CR; Friedberg T
Biochem J; 2001 Jun; 356(Pt 2):613-9. PubMed ID: 11368792
[TBL] [Abstract][Full Text] [Related]
17. Cytochrome P450 dependent metabolism of the new designer drug 1-(3-trifluoromethylphenyl)piperazine (TFMPP). In vivo studies in Wistar and Dark Agouti rats as well as in vitro studies in human liver microsomes.
Staack RF; Paul LD; Springer D; Kraemer T; Maurer HH
Biochem Pharmacol; 2004 Jan; 67(2):235-44. PubMed ID: 14698036
[TBL] [Abstract][Full Text] [Related]
18. Krüppel-like factor 9 promotes hepatic cytochrome P450 2D6 expression during pregnancy in CYP2D6-humanized mice.
Koh KH; Pan X; Zhang W; McLachlan A; Urrutia R; Jeong H
Mol Pharmacol; 2014 Dec; 86(6):727-35. PubMed ID: 25217496
[TBL] [Abstract][Full Text] [Related]
19. Difference in desipramine metabolic profile between wild-type and CYP2D6-humanized mice.
Shen HW; Yu AM
Drug Metab Lett; 2009 Dec; 3(4):234-41. PubMed ID: 19995332
[TBL] [Abstract][Full Text] [Related]
20. Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection.
Holdener M; Hintermann E; Bayer M; Rhode A; Rodrigo E; Hintereder G; Johnson EF; Gonzalez FJ; Pfeilschifter J; Manns MP; Herrath Mv; Christen U
J Exp Med; 2008 Jun; 205(6):1409-22. PubMed ID: 18474629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
